Wide Ranks

INAB

IN8bio, Inc.

0.2962

Top Statistics
Market Cap 21 M Forward PE -1.01 Revenue Growth 0.00 %
Current Ratio 2.67 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.3930 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 10 M Total Cash Per Share 0.2180 Total Debt 5 M
Total Debt To Equity 43.30 Current Ratio 2.67 Book Value Per Share 0.5760
All Measures
Short Ratio 51.00 % Message Board Id finmb_556676116 Shares Short Prior Month 176510
Return On Equity -1.80 City New York Uuid b965db48-c280-3140-b968-9f1daf98eafd
Previous Close 0.3100 First Trade Date Epoch Utc 1 B Book Value 0.5760
Beta -0.0690 Total Debt 5 M Volume 292202
Price To Book 0.5142 Fifty Two Week Low 0.2170 Total Cash Per Share 0.2180
Shares Short Previous Month Date 1 B Target Median Price 4.75 Max Age 86400
Recommendation Mean 2.00 Sand P52 Week Change 0.3133 Target Mean Price 4.75
Net Income To Common -31958000 Short Percent Of Float 0.0183 Implied Shares Outstanding 72 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 341120
Average Volume10days 341120 Total Cash 10 M Next Fiscal Year End 1 B
Held Percent Insiders 0.2156 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.3100 Target Low Price 1.50
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.2970 Open 0.3100
Free Cashflow -12407375 State NY Dividend Yield 0.00 %
Return On Assets -0.7764 Time Zone Short Name EST Trailing Eps -0.7400
Day Low 0.2910 Address1 350 5th Avenue Shares Outstanding 72 M
Price Hint 4 Target High Price 8.00 Website https://in8bio.com
52 Week Change -0.6434 Average Volume 1 M Forward Eps -0.3000
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 214.70 %
Is_sp_500 False Regular Market Day High 0.3210 Profit Margins 0.00 %
Debt To Equity 43.30 Fifty Two Week High 2.48 Day High 0.3210
Shares Short 1 M Regular Market Open 0.3100 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0138
Operating Cashflow -24573000 Currency USD Time Zone Full Name America/New_York
Market Cap 21 M Is_nasdaq_100 False Zip 10118
Quote Type EQUITY Industry Biotechnology Long Name IN8bio, Inc.
Regular Market Day Low 0.2910 Held Percent Institutions 0.4646 Current Price 0.2962
Address2 Suite 5330 Enterprise To Ebitda -0.3930 Financial Currency USD
Current Ratio 2.67 Industry Disp Biotechnology Number Of Analyst Opinions 4
Country United States Float Shares 25 M Two Hundred Day Average 0.7727
Enterprise Value 12 M Forward PE -1.01 Regular Market Volume 292202
Ebitda -30632000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors.

Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.

The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types.

The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.

IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.